Press Releases

Investors

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Arrowhead Pharmaceuticals Presents New Preclinical Data on ARO-ENaC for Treatment of Cystic Fibrosis
PASADENA, Calif. --(BUSINESS WIRE)--May 21, 2018-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced the presentation of new preclinical data on ARO-ENaC, formerly referred to as ARO-Lung1, for the treatment of cystic fibrosis (CF), at the American Thoracic Society (ATS) 2018
View HTML
Toggle Summary Arrowhead Doses First Hepatitis B Patients in Multiple Dose Portion of Phase 1/2 Study of ARO-HBV
PASADENA, Calif. --(BUSINESS WIRE)--May 14, 2018-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has dosed the first 3 hepatitis B virus (HBV) patients in the multiple-ascending dose portion of its ongoing Phase 1/2 study of ARO-HBV, the company’s third generation
View HTML
Toggle Summary Arrowhead Pharmaceuticals Presents Preclinical Data on Expanding Cardiometabolic Pipeline
PASADENA, Calif. --(BUSINESS WIRE)--May 11, 2018-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced the presentation of new preclinical data on its expanding pipeline of RNA interference (RNAi) therapeutics for cardiometabolic diseases, including ARO-ANG3, which targets
View HTML
Toggle Summary Arrowhead Pharmaceuticals Reports Fiscal 2018 Second Quarter Results
Conference Call and Webcast Today at 4:30 p.m. EDT PASADENA, Calif. --(BUSINESS WIRE)--May 8, 2018-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2018 second quarter ended March 31, 2018 . The company is hosting a conference call at 4:30 p.m.
View HTML
Toggle Summary Arrowhead Pharmaceuticals to Present Preclinical Data on Emerging Pipeline of RNAi Therapeutics
PASADENA, Calif. --(BUSINESS WIRE)--May 1, 2018-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will present preclinical data on ARO-ANG3 and ARO-APOC3, its two candidates targeting cardiometabolic diseases, and ARO-ENaC, formerly referred to as ARO-Lung1, its first
View HTML
Toggle Summary Arrowhead Pharmaceuticals to Webcast Fiscal 2018 Second Quarter Results
PASADENA, Calif. --(BUSINESS WIRE)--Apr. 24, 2018-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on May 8, 2018 , at 4:30 p.m. EDT to discuss its financial results for the fiscal 2018 second quarter ended March 31, 2018 .
View HTML
Toggle Summary Arrowhead Pharmaceuticals Presents ARC-520 Clinical Data at The International Liver Congress™
PASADENA, Calif. --(BUSINESS WIRE)--Apr. 11, 2018-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced the presentation of clinical data on ARC-520, the company’s prior generation investigational medicine for the treatment of chronic hepatitis B infection, at The International Liver
View HTML
Toggle Summary Arrowhead Pharmaceuticals Announces Multiple Presentations at The International Liver Congress™
PASADENA, Calif. --(BUSINESS WIRE)--Mar. 28, 2018-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will present clinical and pre-clinical data on the company’s investigational medicines for the treatment of chronic hepatitis B infection (ARC-520 and ARO-HBV) and liver disease
View HTML
Toggle Summary Arrowhead Begins Dosing in Phase 1/2 Study of ARO-HBV for Treatment of Chronic Hepatitis B
PASADENA, Calif. --(BUSINESS WIRE)--Mar. 27, 2018-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has dosed the first subjects in a Phase 1/2 clinical study of ARO-HBV, which is being developed as a potentially curative therapy for patients with chronic hepatitis B virus
View HTML
Toggle Summary Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)
PASADENA, Calif. --(BUSINESS WIRE)--Mar. 20, 2018-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on March 16, 2018 , the Board of Directors approved "inducement" grants to six new employees under Rule 5635(c)(4) of
View HTML